Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo(The University of Texas MD Anderson Cancer Center), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center)
Cited by 60
Related Papers
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|181